TB 222 023
Alternative Names: TB-222-023Latest Information Update: 08 Aug 2023
At a glance
- Originator Twist Bioscience
- Developer Congenital Hyperinsulinism Center at Childrens Hospital of Philadelphia; Twist Bioscience
- Class Antibodies; Antihypoglycaemics
- Mechanism of Action Glucagon-like peptide-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Congenital hyperinsulinism
Most Recent Events
- 26 Jun 2023 TB 222 023 is available for licensing as of 26 Jun 2023. https://www.twistbioscience.com/landing-page/Antibody-Licensing-Opportunities
- 26 Jun 2023 Preclinical trials in Congenital-hyperinsulinism in USA (Parenteral) (before June 2023)
- 26 Jun 2023 Pharmacodynamics data from a preclinical study inCongenital hyperinsulinism released by Twist Bioscience